On September 08, 2022, the Food and Drug Administration (FDA) issued a warning for patients and health specialists after it […]
On August 05, 2022, the U.S. FDA approved Enhertu (T-DXd) or (trastuzumab deruxtecan), an IV infusion to treat patients with […]
The Food and Drug Administration has granted Enhertu (trastuzumab deruxtecan) Breakthrough Therapy Designation (BTD) in the US to treat adult […]
A novel breast cancer jab will lessen the time period patients have to pass in hospital from two-and-a-half hours to […]
According to a study, “the importance of surgery together with the systemic treatments or with systemic treatments and radiation therapy […]
Being the most frequently occurring cancer in women, nearly 2.1 million women are diagnosed with breast cancer every year. Due […]